Incidentally found mucinous epithelial tumors of the appendix with or without pseudomyxoma peritonei: diagnostic and therapeutic algorithms based on current evidence

References

• Johansson J, Andersson RE, Landerholm K, et al. Incidence of appendiceal malignancies in Sweden between 1970 and 2012. World J Surg. 2020;44(12):4086–4092.
   PubMed Web of Science ®Google Scholar
• Mikaeel RR, Young JP, Hardingham JE, et al. Appendiceal neoplasm incidence and mortality rates are on the rise in Australia. Expert Rev Gastroenterol Hepatol. 2021;15(2):203–210.
   PubMed Web of Science ®Google Scholar
• Singh H, Koomson AS, Decker KM, et al. Continued increasing incidence of malignant appendiceal tumors in Canada and the United States: a population-based study. Cancer. 2020;126(10):2206–2216.
   PubMed Web of Science ®Google Scholar
• Stoffel EM, Murphy CC. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. Gastroenterology. 2020;158(2):341–353.
   PubMed Web of Science ®Google Scholar
• Mällinen J, Rautio T, Grönroos J, et al. Risk of appendiceal neoplasm in periappendicular abscess in patients treated with interval appendectomy vs follow-up with magnetic resonance imaging: 1-year outcomes of the peri-appendicitis acuta randomized clinical trial. JAMA Surg. 2019;154(3):200–207.
   PubMed Web of Science ®Google Scholar
• Patrick-Brown TDJH, Carr NJ, Swanson DM, et al. Estimating the prevalence of pseudomyxoma peritonei in Europe using a novel statistical method. Ann Surg Oncol. 2021;28(1):252–257.
   PubMed Web of Science ®Google Scholar
• Shariff US, Chandrakumaran K, Dayal S, et al. Mode of presentation in 1070 patients with perforated epithelial appendiceal tumors, predominantly with pseudomyxoma peritonei. Dis Colon Rectum. 2020;63(9):1257–1264.
   PubMed Web of Science ®Google Scholar
• Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol. 2016;40(1):14–26.
   PubMed Web of Science ®Google Scholar
• Stein A, Strong E, Clark Gamblin T, et al. Molecular and genetic markers in appendiceal mucinous tumors: a systematic review. Ann Surg Oncol. 2020;27(1):85–97.
   PubMed Web of Science ®Google Scholar
• Tokunaga R, Xiu J, Johnston C, et al. Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. Clin Cancer Res. 2019;25(10):3096–3103.
   PubMed Web of Science ®Google Scholar
• Sinno SAJ, Jurdi NMH. Goblet cell tumors of the appendix: a review. Ann Diagn Pathol. 2019;43:151401.
   PubMed Web of Science ®Google Scholar
• Tang LH, Shia J, Soslow RA, et al. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol. 2008;32(10):1429–1443.
   PubMed Web of Science ®Google Scholar
• Aziz M, Kasi A. Krukenberg tumor. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
   Google Scholar
• Low RN, Barone RM, Rousset P. Peritoneal MRI in patients undergoing cytoreductive surgery and HIPEC: history, clinical applications, and implementation. Eur J Surg Oncol. 2021;47(1):65–74.
   PubMed Web of Science ®Google Scholar
• Smeenk RM, van Velthuysen ML, Verwaal VJ, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196–201.
   PubMed Web of Science ®Google Scholar
• van Eden WJ, Kok NFM, Snaebjornsson P, et al. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms. BJS Open. 2019;3(3):376–386.
   PubMed Web of Science ®Google Scholar
• Carmignani CP, Hampton R, Sugarbaker CE, Chang D, et al. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol. 2004;87(4):162–166.
   PubMed Web of Science ®Google Scholar
• Jedrzkiewicz J, Tateishi Y, Kirsch R, et al. Impact of referral center pathology review on diagnosis and management of patients with appendiceal neoplasms. Arch Pathol Lab Med. 2020;144(6):764–768.
   PubMed Web of Science ®Google Scholar
• Honoré C, Caruso F, Dartigues P, et al. Strategies for preventing pseudomyxoma peritonei after resection of a mucinous neoplasm of the appendix. Anticancer Res. 2015;35(9):4943–4947.
   PubMed Web of Science ®Google Scholar
• Young S, Sueda SK, Hotta M, et al. Surgical management of appendiceal mucinous neoplasm: is appendectomy sufficient? J Surg Oncol. 2020;122(6):1173–1178.
   PubMed Web of Science ®Google Scholar
• Hegg KS, Mack LA, Bouchard-Fortier A, et al. Macroscopic and microscopic characteristics of low grade appendiceal mucinous neoplasms (LAMN) on appendectomy specimens and correlations with pseudomyxoma peritonei development risk. Ann Diagn Pathol. 2020;48:151606.
   PubMed Web of Science ®Google Scholar
• Enomoto LM, Choudry MH, Bartlett DL, et al. Outcomes after adjuvant hyperthermic intraperitoneal chemotherapy for high-risk primary appendiceal neoplasms after complete resection. Ann Surg Oncol. 2020;27(1):107–114.
   PubMed Web of Science ®Google Scholar
• Yantiss RK, Shia J, Klimstra DS, et al. Prognostic significance of localized extra-appendiceal mucin deposition in appendiceal mucinous neoplasms. Am J Surg Pathol. 2009;33(2):248–255.
   PubMed Web of Science ®Google Scholar
• Ang CS, Shen JP, Hardy-Abeloos CJ, et al. Genomic landscape of appendiceal neoplasms. J Clin Oncol Precis Oncol. 2018;2(2):1–18.
   PubMed Web of Science ®Google Scholar
• Asare EA, Compton CC, Hanna NN, et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the National Cancer Data Base. Cancer. 2016;122(2):213–221.
   PubMed Web of Science ®Google Scholar
• Zhang W, Tan C, Xu M, et al. Appendiceal mucinous neoplasm mimics ovarian tumors: challenges for preoperative and intraoperative diagnosis and clinical implication. Eur J Surg Oncol. 2019;45(11):2120–2125.
   PubMed Web of Science ®Google Scholar
• Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma. N Engl J Med. 2019;380(13):1256–1266.
   PubMed Web of Science ®Google Scholar
• Verheij FS, Bakkers C, Eden WJ, et al. Comparison of the Peritoneal Cancer Index and Dutch region count as tools to stage patients with peritoneal metastases of colorectal cancer. BJS Open. 2020;4(6):1153–1161.
   PubMed Web of Science ®Google Scholar
• Azaïs H, Vignion-Dewalle AS, Carrier M, et al. Microscopic peritoneal residual disease after complete macroscopic cytoreductive surgery for advanced high grade serous ovarian cancer. J Clin Med. 2020;10(1):41.
   PubMed Web of Science ®Google Scholar
• Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–2456.
   PubMed Web of Science ®Google Scholar
• Ceelen W, Braet H, van Ramshorst G, et al. Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion. Expert Opin Drug Deliv. 2020;17(4):511–522.
   PubMed Web of Science ®Google Scholar
• Funder JA, Jepsen KV, Stribolt K, et al. Palliative surgery for pseudomyxoma peritonei. Scand J Surg. 2016;105(2):84–89.
   PubMed Web of Science ®Google Scholar
• Dayal S, Taflampas P, Riss S, et al. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum. 2013;56(12):1366–1372.
   PubMed Web of Science ®Google Scholar
• Sheehan LA, Mehta AM, Sawan S, et al. Preserving fertility in pseudomyxoma peritonei, a novel approach. Pleura Peritoneum. 2017;2(1):33–36.
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2008;15(2):526–534.
   PubMed Web of Science ®Google Scholar
• Shaib WL, Martin LK, Choi M, et al. Hyperthermic intraperitoneal chemotherapy following cytoreductive surgery improves outcome in patients with primary appendiceal mucinous adenocarcinoma: a pooled analysis from three tertiary care centers. Oncologist. 2015;20(8):907–914.
   PubMed Web of Science ®Google Scholar
• Munoz-Zuluaga CA, King MC, Ledakis P, et al. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin. Eur J Surg Oncol. 2019;45(9):1598–1606.
   PubMed Web of Science ®Google Scholar
• Milovanov V, Sardi A, Ledakis P, et al. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). Eur J Surg Oncol. 2015;41(5):707–712.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Bijelic L, Chang D, et al. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102(6):576–581.
   PubMed Web of Science ®Google Scholar
• Bijelic L, Kumar AS, Stuart OA, Sugarbaker PH. Systemic chemotherapy prior to cytoreductive surgery and HIPEC for carcinomatosis from appendix cancer: impact on perioperative outcomes and short-term survival. Gastroenterol Res Pract. 2012;2012:163284.
   PubMed Web of Science ®Google Scholar
• Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010;116(2):316–322.
   PubMed Web of Science ®Google Scholar
• Lieu CH, Lambert LA, Wolff RA, et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012;23(3):652–658.
   PubMed Web of Science ®Google Scholar
• Tejani MA, ter Veer A, Milne D, et al. Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. J Natl Compr Canc Netw. 2014;12(8):1123–1130.
   PubMed Web of Science ®Google Scholar
• Hiraide S, Komine K, Sato Y, et al. Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei. Int J Clin Oncol. 2020;25(4):774–781.
   PubMed Web of Science ®Google Scholar
• Farquharson AL, Pranesh N, Witham G, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer. 2008;99(4):591–596.
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Berenato R, Maggi C, et al. GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. J Transl Med. 2016;14(1):125.
   PubMed Web of Science ®Google Scholar
• Liu W, Liu L, Wang R, et al. Bevacizumab combined with oxaliplatin/capecitabine in patient with refractory and recurrent mucinous adenocarcinoma of the appendix: a case report. Front Oncol. 2019;9:55.
   PubMed Web of Science ®Google Scholar
• Choe JH, Overman MJ, Fournier KF, et al. Improved survival with anti-VEGF therapy in the treatment of unresectable appendiceal epithelial neoplasms. Ann Surg Oncol. 2015;22(8):2578–2584.
   PubMed Web of Science ®Google Scholar
• Sun WL, Hutarew G, Gradl J, et al. Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine. Cancer Biol Ther. 2009;8(15):1459–1462.
   PubMed Web of Science ®Google Scholar
• Sgarbura O, Hübner M, Alyami M, et al. Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: a multicenter study. Eur J Surg Oncol. 2019;45(12):2386–2391.
   PubMed Web of Science ®Google Scholar
• Tempfer CB, Solass W, Buerkle B, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: a case report. Gynecol Oncol Rep. 2014;10:32–35.
   PubMedGoogle Scholar
• Kolla BC, Petersen A, Chengappa M, et al. Impact of adjuvant chemotherapy on outcomes in appendiceal cancer. Cancer Med. 2020;9(10):3400–3406.
   PubMed Web of Science ®Google Scholar
• Blackham AU, Swett K, Eng C, et al. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2014;109(7):740–745.
   PubMed Web of Science ®Google Scholar